Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Non-Small Cell Lung Cancer.

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase ...

Future Prospects: The future of the Vietnam platinum-based cancer drug market is promising. As cancer incidence continues to rise and as oncology research progresses, the demand for these drugs is ...

A mother-of-one has warned women not to dismiss a telltale sign of deadly ovarian cancer that is often mistaken for an upcoming period. Sophie Casey, 28, from Leeds, was diagnosed in October with ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

A new study from Cedars-Sinai Cancer reveals a potential way to overcome tumor resistance to a common chemotherapy drug ...

"The first platinum-based drug, cisplatin, has a powerful effect on cancer by binding to nuclear DNA, but it also affects normal cells and can cause serious side effects. We had data showing that ...

Erratum: A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease Seventy patients were enrolled, 33 (47%) had a ...